Pipeline

A new generation of medicines.

OrphAI Therapeutics is advancing the following drugs into clinical trials/development: LAM-001 for Group 1 and Group 3 Pulmonary Hypertension (PH) and Bronchiolitis Obliterans Syndrome post lung transplant (BOS); AIT-102 for transcriptionally dysregulated cancers.

Program
Preclinical
Phase 1
Phase 2
Phase 3
Preclinical
Phase 1
Phase 2
Phase 3

Preclinical
Phase 1
Phase 2
Phase 3

Preclinical
Phase 1
Phase 2
Phase 3

Program
AIT-101*

Amyotrophic Lateral Sclerosis

Hide Details
Details
Preclinical
Phase 1
Phase 2
Phase 3

* Further development of AIT-101 is on hold pending non-dilutive funding